3 hours Black Diamond Therapeutics (NASDAQ:BDTX) Receives “Buy” Rating from HC Wainwright MarketBeat
HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday.
HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday.